\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ examination\\ reveals\\ no\\ focal\\ neurologic\\ deficit\\.\ \(0\)\
\-\ the\\ patient\\ passed\\ away\\ four\\ months\\ after\\ the\\ last\\ follow\\ up\\ mr\\ exam\\ \\(one\\ year\\ after\\ the\\ diagnosis\\ of\\ gbm\\)\\.\\ he\\ had\\ been\\ receiving\\ a\\ combination\\ of\\ chemotherapy\\ and\\ radiotherapy\\.\ \(0\)\
\-\ a\\ large\\ \\,\\ heterogeneous\\ t2\\ hyperintense\\,\\ ring\\ enhancing\\ mass\\ lesion\\ is\\ noted\\ in\\ the\\ left\\ temporoparietooccipital\\ area\\.\\ the\\ mass\\ lesion\\ is\\ surrounded\\ by\\ vasogenic\\ edema\\ and\\ exerts\\ significant\\ mass\\ effect\\ in\\ the\\ adjacent\\ cerebral\\ parenchyma\\ and\\ left\\ occipital\\ horn\\.\ \(0\)\
\-\ the\\ \\ combination\\ of\\ findings\\ are\\ consistent\\ with\\ a\\ high\\ grade\\ glioma\\.\ \(0\)\
\-\ glioblastoma\\ multiforme\ \(8\)\
\-\ abscess\ \(594\)\
\-\ metastasis\ \(206\)\
\-\ primary\\ cns\\ lymphoma\ \(0\)\
\-\ demyelinating\\ disease\ \(15\)\
\-\ arteriovenous\\ malformation\\.\ \(2\)\
\-\ 49\\-year\\ old\\ man\\ presents\\ with\\ progressive\\ onset\\ of\\ headache\\ and\\ balance\\ disorder\\.\ \(1\)\
\-\ we\\ have\\ not\\ used\\ dsc\\ mr\\ imaging\\ in\\ the\\ last\\ two\\ follow\\ up\\ exams\\ \\ because\\ there\\ was\\ an\\ obvious\\ significant\\ increase\\ in\\ the\\ size\\ of\\ the\\ enhancing\\ lesion\\ an\\ the\\ surgical\\ margin\\ compared\\ to\\ the\\ exam\\ obtained\\ at\\ three\\ months\\ after\\ the\\ surgical\\ resection\\ and\\ the\\ initiation\\ of\\ the\\ chemoradiotherapy\\.\\ \ \(0\)\
\-\ follow\\ up\\ exam\\ obtained\\ at\\ three\\ months\\ after\\ the\\ surgical\\ resection\\ and\\ the\\ initiation\\ of\\ the\\ chemoradiotherapy\\ revealed\\ an\\ small\\ enhancing\\ lesion\\ which\\ is\\ characterized\\ by\\ a\\ high\\ rcbv\\ of\\ 4\\.0\\ \\,compared\\ to\\ the\\ normal\\ contralateral\\ white\\ matter\\,\\ and\\ an\\ interval\\ increase\\ in\\ size\\ compared\\ to\\ the\\ size\\ of\\ the\\ enhancing\\ lesion\\ in\\ the\\ previous\\ exam\\.\\ \ \(0\)\
\-\ this\\ enhancing\\ lesion\\ represented\\ \\ predominantly\\ tumor\\ progression\\.\\ small\\ foci\\ of\\ reactive\\ radiation\\-induced\\ changes\\ cannot\\ be\\ excluded\\.\ \(0\)\
\-\ if\\ this\\ enhancing\\ lesion\\ represented\\ pseudoprogression\\ \\,\\ this\\ increased\\ enhancement\\ \\ would\\ have\\ been\\ stable\\ or\\ decreased\\ on\\ follow\\-up\\ studies\\.\\ conversely\\,\\ \\ the\\ enhancing\\ nodule\\ was\\ increasing\\ in\\ size\\ on\\ follow\\ up\\ exams\\.\ \(0\)\
\-\ importantly\\,\\ we\\ should\\ keep\\ in\\ mind\\ that\\ the\\ patient\\ was\\ clinically\\ getting\\ worse\\ and\\ worse\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ enhancing\\:\\ 0\\.06232450076476184\ \(0\)\
\-\ chemoradiotherapy\\:\\ 0\\.051275123822580655\ \(0\)\
\-\ initiation\\:\\ 0\\.043975374396214476\ \(0\)\
\-\ represented\\:\\ 0\\.043975374396214476\ \(0\)\
\-\ lesion\\:\\ 0\\.04047802851163848\ \(0\)\
\-\ size\\:\\ 0\\.03807144015121291\ \(0\)\
\-\ follow\\:\\ 0\\.03608238500925494\ \(0\)\
\-\ compared\\:\\ 0\\.03605004710332896\ \(0\)\
\-\ exams\\:\\ 0\\.0320699958631377\ \(0\)\
\-\ up\\:\\ 0\\.030536174764840177\ \(0\)\
\-\ we\\:\\ 0\\.029887244587576002\ \(0\)\
\-\ temporoparietooccipital\\:\\ 0\\.029287436624473417\ \(0\)\
\-\ 49\\-year\\:\\ 0\\.029287436624473417\ \(0\)\
\-\ dsc\\:\\ 0\\.029287436624473417\ \(0\)\
\-\ pseudoprogression\\:\\ 0\\.029287436624473417\ \(0\)\
\-\ combination\\:\\ 0\\.028602384833552482\ \(0\)\
\-\ radiation\\-induced\\:\\ 0\\.025637561911290328\ \(0\)\
\-\ worse\\:\\ 0\\.025150036561953904\ \(0\)\
\-\ exam\\:\\ 0\\.0249466304312231\ \(0\)\
\-\ rcbv\\:\\ 0\\.024681807517762815\ \(0\)\
\-\ last\\:\\ 0\\.02425735847204641\ \(0\)\
\-\ increase\\:\\ 0\\.02381667645921536\ \(0\)\
\-\ after\\:\\ 0\\.023495032592813322\ \(0\)\
\-\ conversely\\:\\ 0\\.02333474735793503\ \(0\)\
\-\ months\\:\\ 0\\.023261873369003993\ \(0\)\
\-\ exerts\\:\\ 0\\.02282261885352553\ \(0\)\
\-\ importantly\\:\\ 0\\.02163765226236695\ \(0\)\
\-\ 4\\.0\\:\\ 0\\.021031932804579725\ \(0\)\
\-\ mind\\:\\ 0\\.02051980430017023\ \(0\)\
\-\ keep\\:\\ 0\\.020290592102539164\ \(0\)\
\-\ obtained\\:\\ 0\\.0201851568155737\ \(0\)\
\-\ three\\:\\ 0\\.01914036032124193\ \(0\)\
\-\ getting\\:\\ 0\\.01833781248492415\ \(0\)\
\-\ mr\\:\\ 0\\.01804119250462747\ \(0\)\
\-\ surgical\\:\\ 0\\.017902542560645714\ \(0\)\
\-\ resection\\:\\ 0\\.017707080767576204\ \(0\)\
\-\ demyelinating\\:\\ 0\\.01757195315398783\ \(0\)\
\-\ balance\\:\\ 0\\.01738205809139664\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.01729103159907732\ \(0\)\
\-\ passed\\:\\ 0\\.017116135474541036\ \(0\)\
\-\ gbm\\:\\ 0\\.016791755176986497\ \(0\)\
\-\ away\\:\\ 0\\.01649624857892505\ \(0\)\
\-\ multiforme\\:\\ 0\\.01649624857892505\ \(0\)\
\-\ receiving\\:\\ 0\\.01642630369786913\ \(0\)\
\-\ surrounded\\:\\ 0\\.01622489299416004\ \(0\)\
\-\ an\\:\\ 0\\.01570318756524558\ \(0\)\
\-\ contralateral\\:\\ 0\\.015684962995828566\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.015630048371405938\ \(0\)\
\-\ high\\:\\ 0\\.015538512033732995\ \(0\)\
\-\ been\\:\\ 0\\.015447142122684327\ \(0\)\
\-\ horn\\:\\ 0\\.015419040378972959\ \(0\)\
\-\ vasogenic\\:\\ 0\\.015368317880199576\ \(0\)\
\-\ excluded\\:\\ 0\\.015368317880199576\ \(0\)\
\-\ significant\\:\\ 0\\.015268087382420088\ \(0\)\
\-\ arteriovenous\\:\\ 0\\.014899618218206536\ \(0\)\
\-\ deficit\\:\\ 0\\.01464717334452573\ \(0\)\
\-\ cns\\:\\ 0\\.014527797898591967\ \(0\)\
\-\ obvious\\:\\ 0\\.014337902836000775\ \(0\)\
\-\ characterized\\:\\ 0\\.014123489144513827\ \(0\)\
\-\ progression\\:\\ 0\\.014123489144513827\ \(0\)\
\-\ interval\\:\\ 0\\.01392207844080474\ \(0\)\
\-\ reactive\\:\\ 0\\.013437986044853268\ \(0\)\
\-\ margin\\:\\ 0\\.013354577669002516\ \(0\)\
\-\ predominantly\\:\\ 0\\.013300113184697942\ \(0\)\
\-\ occipital\\:\\ 0\\.013246527198219924\ \(0\)\
\-\ ring\\:\\ 0\\.013193791818963147\ \(0\)\
\-\ small\\:\\ 0\\.013080234447715075\ \(0\)\
\-\ glioma\\:\\ 0\\.012799580709988675\ \(0\)\
\-\ disorder\\:\\ 0\\.012753437480219015\ \(0\)\
\-\ clinically\\:\\ 0\\.012447223328060687\ \(0\)\
\-\ four\\:\\ 0\\.012324162624803714\ \(0\)\
\-\ have\\:\\ 0\\.012295269623688317\ \(0\)\
\-\ foci\\:\\ 0\\.012186126070275898\ \(0\)\
\-\ parenchyma\\:\\ 0\\.012090925885025479\ \(0\)\
\-\ neurologic\\:\\ 0\\.011855462962810672\ \(0\)\
\-\ mass\\:\\ 0\\.011845126315092004\ \(0\)\
\-\ hyperintense\\:\\ 0\\.011786246727253057\ \(0\)\
\-\ stable\\:\\ 0\\.011701706309774107\ \(0\)\
\-\ nodule\\:\\ 0\\.011701706309774107\ \(0\)\
\-\ increasing\\:\\ 0\\.011635589518022295\ \(0\)\
\-\ malformation\\:\\ 0\\.011323410805669036\ \(0\)\
\-\ progressive\\:\\ 0\\.011220727956954495\ \(0\)\
\-\ in\\:\\ 0\\.011199926382465248\ \(0\)\
\-\ matter\\:\\ 0\\.011177674320268432\ \(0\)\
\-\ reveals\\:\\ 0\\.011107135383039944\ \(0\)\
\-\ previous\\:\\ 0\\.011024419264695336\ \(0\)\
\-\ the\\:\\ 0\\.011023198780355544\ \(0\)\
\-\ used\\:\\ 0\\.010890977265607846\ \(0\)\
\-\ grade\\:\\ 0\\.01081341127226236\ \(0\)\
\-\ metastasis\\:\\ 0\\.010627067529235637\ \(0\)\
\-\ studies\\:\\ 0\\.01060299308232279\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.010439186567425268\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.01017589961840819\ \(0\)\
\-\ would\\:\\ 0\\.010102879994757773\ \(0\)\
\-\ effect\\:\\ 0\\.010051688548402807\ \(0\)\
\-\ because\\:\\ 0\\.009931954540152983\ \(0\)\
\-\ was\\:\\ 0\\.009849942081863988\ \(0\)\
\-\ cerebral\\:\\ 0\\.009835370437754388\ \(0\)\
\-\ headache\\:\\ 0\\.009750782184603981\ \(0\)\
\-\ this\\:\\ 0\\.009579440664260462\ \(0\)\
\-\ by\\:\\ 0\\.00945429171591279\ \(0\)\
\-\ white\\:\\ 0\\.009415628613661188\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.009236003293826386\ \(0\)\
\-\ revealed\\:\\ 0\\.009111208936432203\ \(0\)\
\-\ should\\:\\ 0\\.009050526717238539\ \(0\)\
\-\ area\\:\\ 0\\.008976200146625472\ \(0\)\
\-\ adjacent\\:\\ 0\\.008976200146625472\ \(0\)\
\-\ abscess\\:\\ 0\\.008976200146625472\ \(0\)\
\-\ onset\\:\\ 0\\.008961532312043687\ \(0\)\
\-\ examination\\:\\ 0\\.008825325699251048\ \(0\)\
\-\ decreased\\:\\ 0\\.00844105117184239\ \(0\)\
\-\ primary\\:\\ 0\\.008409914494670087\ \(0\)\
\-\ not\\:\\ 0\\.008204775227521166\ \(0\)\
\-\ changes\\:\\ 0\\.008136372014069969\ \(0\)\
\-\ two\\:\\ 0\\.008130668563508324\ \(0\)\
\-\ lymphoma\\:\\ 0\\.008113616725546464\ \(0\)\
\-\ focal\\:\\ 0\\.008107952173217282\ \(0\)\
\-\ t2\\:\\ 0\\.0080351786337221\ \(0\)\
\-\ edema\\:\\ 0\\.008029646144290003\ \(0\)\
\-\ he\\:\\ 0\\.007920888179511693\ \(0\)\
\-\ if\\:\\ 0\\.0077034665574107495\ \(0\)\
\-\ one\\:\\ 0\\.007693459745218087\ \(0\)\
\-\ at\\:\\ 0\\.007692778424130452\ \(0\)\
\-\ enhancement\\:\\ 0\\.007609597229644638\ \(0\)\
\-\ physical\\:\\ 0\\.006965133785984181\ \(0\)\
\-\ consistent\\:\\ 0\\.006961123816714961\ \(0\)\
\-\ increased\\:\\ 0\\.006945132165447361\ \(0\)\
\-\ noted\\:\\ 0\\.0067289740480152615\ \(0\)\
\-\ man\\:\\ 0\\.006714059279368768\ \(0\)\
\-\ imaging\\:\\ 0\\.006651408054669777\ \(0\)\
\-\ tumor\\:\\ 0\\.006618711965484423\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0065190010989382725\ \(0\)\
\-\ can\\:\\ 0\\.0064392769185018925\ \(0\)\
\-\ left\\:\\ 0\\.006352858932045945\ \(0\)\
\-\ \\,\\:\\ 0\\.006295582919006683\ \(0\)\
\-\ large\\:\\ 0\\.00620778216555176\ \(0\)\
\-\ had\\:\\ 0\\.00612574690777644\ \(0\)\
\-\ findings\\:\\ 0\\.006042647627209168\ \(0\)\
\-\ presents\\:\\ 0\\.005799482709328657\ \(0\)\
\-\ patient\\:\\ 0\\.005691640736985967\ \(0\)\
\-\ is\\:\\ 0\\.005604227027090288\ \(0\)\
\-\ which\\:\\ 0\\.0052994836785466735\ \(0\)\
\-\ a\\:\\ 0\\.0052704292600478575\ \(0\)\
\-\ that\\:\\ 0\\.0049035904603283165\ \(0\)\
\-\ on\\:\\ 0\\.004809907058906499\ \(0\)\
\-\ and\\:\\ 0\\.004784292511155308\ \(0\)\
\-\ disease\\:\\ 0\\.00464032405719503\ \(0\)\
\-\ normal\\:\\ 0\\.0044505397162760835\ \(0\)\
\-\ be\\:\\ 0\\.00437792931343498\ \(0\)\
\-\ to\\:\\ 0\\.004256492775179265\ \(0\)\
\-\ there\\:\\ 0\\.004224968626129531\ \(0\)\
\-\ of\\:\\ 0\\.0038705581660461274\ \(0\)\
\-\ are\\:\\ 0\\.00387001286554685\ \(0\)\
\-\ or\\:\\ 0\\.0033273181028694605\ \(0\)\
\-\ year\\:\\ 0\\.0031764294660229725\ \(0\)\
\-\ old\\:\\ 0\\.002906759458014135\ \(0\)\
\-\ no\\:\\ 0\\.0028586184408764185\ \(0\)\
\-\ \\(\\:\\ 0\\.0023998728446639884\ \(0\)\
\-\ \\)\\:\\ 0\\.0023705571166554988\ \(0\)\
\-\ \\.\\:\\ 0\\.001769079871960778\ \(0\)\
\-\ with\\:\\ 0\\.0007774363859793338\ \(0\)\
